Schonfeld Strategic Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,500	Closed	-$34K	–	3273
2022 Q1	$34K	Buy	+25,500	New	+$41.3K	﹤0.01%	2372
2019 Q4	–	Sell	-52,700	Closed	-$220K	–	1548
2019 Q3	$220K	Sell	52,700 -37,700	-42%	-$301K	0.01%	885
2019 Q2	$1.19M	Buy	90,400 +27,400	+43%	+$336K	0.04%	403
2019 Q1	$600K	Buy	+63,000	New	+$249K	0.02%	642

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Schonfeld Strategic Advisors's PHAS Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 25,500 shares — an estimated $34K sold.

Schonfeld Strategic Advisors first reported a position in PHAS in Q1 2019 and held it in 4 quarters. The position peaked at $1.19M in Q2 2019. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

Schonfeld Strategic Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 25,500 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $34K.
Schonfeld Strategic Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 4 quarters.
Schonfeld Strategic Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.19M in Q2 2019.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.